STUDY
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study BACKGROUND • Coronary artery bypass grafting (CABG) reduces mortality in patients with extensive coronary artery disease (CAD)
• One limitation of CABG surgery is early graft failure, mainly caused by thrombotic occlusion, which is associated with a risk of myocardial infarction (MI) and death • Although routine use of aspirin (ASA) prevents early failure, as many as 30% of patients have at least one occluded graft one year after surgery • In the COMPASS trial, rivaroxaban 2.5 mg twice daily plus ASA 100 mg daily compared to ASA 100 mg daily reduced the primary major adverse cardiovascular events (MACE) outcome of cardiovascular (CV) death, stroke, or MI; rivaroxaban 5 mg twice daily alone did not significantly reduce MACE OBJECTIVE
• To determine whether rivaroxaban with or without aspirin would be more effective than aspirin for preventing bypass graft failure at one year in patients with CAD who had recent CABG surgery METHODS
• Design: 3x2 partial factorial, multi-center, double-blind, randomized controlled trial • Duration: 23 months • Inclusion Criteria: stable CAD or PAD, CABG surgery within 4-14 days, at least 2 grafts implanted, estimated glomerular filtration rate of at least 30 ml/min • Exclusion Criteria: a concomitant procedure requiring anticoagulation (e.g. mechanical valve placement), patients with atrial fibrillation requiring anticoagulation • Number Enrolled: 1,448 patients • Regimen: randomized in a 1:1:1 ratio to receive either rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily, rivaroxaban 5 mg twice daily, or aspirin 100 mg daily • Primary Outcome: proportion of coronary bypass grafts that failed with complete occlusion of the graft (analyzed using mixed logistic regression) • Secondary Outcome: proportion of patients with at least one failed graft (analyzed using logistic regression models) • Clinical Efficacy Outcomes: primary composite of CV death, MI, or stroke (analyzed using Cox regression) -Rate of graft occlusion: 7.8% -Rate of graft occlusion: 8.0% • Rivaroxaban + ASA versus ASA Only: OR = 1.13 (95% CI: 0.82 to 1.57; p = 0.45 • Rivaroxaban Only versus ASA Only: OR = 0.95 (95% CI: 0.67 to 1.33; p = 0.75 Secondary Outcome Rivaroxaban 2.5 mg BID + ASA Rivaroxaban 5 mg BID Only ASA Only -86 patients (21.7%) -68 patients (17.8%) -75 patients (20.7%) • Rivaroxaban + ASA versus ASA Only: OR = 1.06 (95% CI: 0.75 to 1.50; p = 0.74) • Rivaroxaban Only versus ASA Only: OR = 0.83 (95% CI: 0.58 to 1.20; p = 0.32) Clinical Efficacy Outcomes Rivaroxaban 2.5 mg BID + ASA Rivaroxaban 5 mg BID Only ASA Only -12 patients (2.4%) -16 patients (3.3%) -16 patients (3.5%) • Rivaroxaban + ASA versus ASA Only: HR = 0.69 (95% CI: 0.33 to 1.47; p = 0.34) • Rivaroxaban Only versus ASA Only: HR = 0.99 (95% CI: 0.50 to 1.99; p = 0.98) Bleeding Outcomes Rivaroxaban 2.5 mg BID + ASA Rivaroxaban 5 mg BID Only ASA Only -2 patients (0.4%) -1 patient (0.2%) -5 patients (1.1%) • Rivaroxaban + ASA versus ASA Only: HR = 0.37 (95% CI: 0.07 to 1.88; p = 0.37 • Rivaroxaban Only versus ASA Only: HR = 0.19 (95% CI: 0.02 to 1.61; p = 0.09
Authors' Conclusions Olivia Rockwell, PharmD/MBA Candidate • Combination of rivaroxaban 2.5 mg twice daily plus ASA 100 mg daily or rivaroxaban 5 mg twice daily alone compared with ASA 100 mg daily alone did not reduce graft failure in patients with recent CABG surgery • In the first 30 days after CABG surgery, there was no fatal bleeding or tamponade despite starting anticoagulation as early as four days after surgery and without a run-in period • The combination of rivaroxaban plus ASA was associated with similar reductions in MACE as observed in the larger COMPASS trial • It is reasonable and safe to use the combination of rivaroxaban 2.5 mg twice daily plus ASA in patients who undergo CABG surgery STRENGTHS/ LIMITATIONS Overall, it would be very difficult to extrapolate the results of this study to actual clinical practice. The study was not powered to detect a benefit in rivaroxaban-based therapy, which was the study's main objective. The most important statistically, and potentially clinically, significant finding was the fact that there was a 2-fold increase in risk of bleeding within the first 30 days with rivaroxaban alone versus aspirin alone. This would be something to consider in patients undergoing CABG therapy who are at high risk of bleeding post-surgery. However, further research is needed. This research should include studies with adequate power to detect a difference in rivaroxaban-based therapy, in patients of varying age groups (40-60, for example), and with more succinct inclusion and exclusion criteria (off-pump only patients, for example). 
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